Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2024 08:00 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics participará en la conferencia BIO-Europe Spring

ROCKVILLE, Maryland, March 11, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), empresa diversificada de fase clínica que investiga tratamientos antineoplásicos y enfermedades...
March 11, 2024 08:00 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

ROCKVILLE, Md., March 11, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related...
February 07, 2024 17:53 ET | Source: Theriva Biologics, Inc.

Theriva Biologics anuncia la recomendación positiva del Comité independiente para la monitorización de los datos de Datos de VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma pancreático ductal metastásico

ROCKVILLE, Md., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), una empresa diversificada en fase clínica que desarrolla terapias diseñadas para tratar el cáncer y...
February 07, 2024 08:00 ET | Source: Theriva Biologics, Inc.

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

ROCKVILLE, Md., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases...
January 16, 2024 13:08 ET | Source: Theriva Biologics, Inc.

Theriva Biologics participará en la Conferencia Anual de Oncología de B. Riley Securities

ROCKVILLE, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), empresa diversificada de fase clínica que investiga tratamientos antineoplásicos y enfermedades...
January 16, 2024 08:00 ET | Source: Theriva Biologics, Inc.

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference

ROCKVILLE, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related...
November 13, 2023 08:00 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2023

- VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma ductal de páncreas metastásico, sigue el curso previsto para completar la inscripción en el...
November 13, 2023 08:00 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024;...
November 07, 2023 11:40 ET | Source: Theriva Biologics, Inc.

Theriva Biologics realizará una teleconferencia y retransmisión por Internet para comentar los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2023

ROCKVILLE, Maryland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y...
November 06, 2023 16:05 ET | Source: Theriva Biologics, Inc.

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results

ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases...